Terminated PHASE1 INTERVENTIONAL 1-arm NCT01902771

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors

Sponsor: Edward Ziga

Conditions Brain Cancer Brain Tumor Glioblastoma Multiforme Glioma High Grade Glioma

Interventions Dendritic Cell Vaccine Imiquimod Leukapheresis Tumor Lysate

Updated 7 times since 2017 Last updated: Mar 8, 2017 Started: Sep 3, 2013 Primary completion: Oct 24, 2016 Completion: Jan 26, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Lack of Accrual

Other Brain Cancer trials with similar outcome

Browse all Brain Cancer trials

This PHASE1 trial investigates Brain Cancer and Brain Tumor and is currently terminated or withdrawn. Edward Ziga leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Mar 2017 — Jun 2018 [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated

▶ Show 2 earlier versions

Feb 2017 — Mar 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Edward Ziga

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States